With affordable and increasingly skilled labour, and a growing commitment to strengthening IPR and infrastructure within the country, India is now transforming itself from an API and generics manufacturer to an innovation-driven manufacturing hub.
Pitching Prime Minister Narendra Modi’s ‘Make in India’ campaign in the United States, Mr. Dilip Shanghvi, the promoter, founder and CEO of Sun Pharmaceutical Industries, on June 8 vowed not just to promote the campaign but to ‘Innovate in India’. For instance, the slow down of the generics market and government tax rebate earnings from global patent fillings encourage Indian pharmaceutical companies, such as Biocon, Dr Reddy’s Lab, Lupin, Wockhardt and many more to drive innovation within their organisations.
Among these companies is Panacea Biotec, a leading vaccine manufacturer producing WHO pre-qualified affordable essential vaccines to India and the world. Ranking as the third largest biotech company and one of the top 50 pharmaceutical companies in India, Panacea Biotec is one of the companies in India focusing on providing innovative, affordable drugs in the country. It is a role model in India, having established presence in more than 20 international markets, including CIS, LatAm, Middle East, Asia and Africa.
At Panacea Biotec, where Mr. R K Suri till recently worked as Chief Executive- Biologicals & currently engaged as Senior Advisor, believes that innovation is the way of life. Quoting the official website, Panacea Biotec has filed more than 1400 patents applications out of which 382 have been granted.
Want to know more about Panacea Biotec & Innovation as its core value, join us at the 14th BioPharma India 2016 in Mumbai this November
Book now to join us.